New drug combo aims to shrink tumors before surgery, possibly sparing organs
NCT ID NCT07281417
Summary
This study is testing if adding an immunotherapy drug called cemiplimab to standard chemotherapy before surgery works better than chemotherapy alone for a type of head and neck cancer. It aims to see if the combination can better shrink tumors, improve survival, and potentially help preserve critical structures like the eye socket. The trial will enroll about 108 adults with advanced sinonasal squamous cell carcinoma who have not yet had surgery.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE III SINONASAL CANCER AJCC V8 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Ohio State University Comprehensive Cancer Center LAO
RECRUITINGColumbus, Ohio, 43210, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.